Delivery Order SPE2DB20D3103-SPE2DB24FM3F2
- Not listed
- This federal contract award is for the delivery of Dupixent 300 mg/2 ml pens to the Defense Logistics Agency (DLA), a defense agency. The $10,103.45 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has an ultimate completion date of April 29, 2024 and was awarded on April 26, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the...
- This federal contract award is for the delivery of Dupixent 300 mg/2 ml pens to the Defense Logistics Agency (DLA), a defense agency. The fixed-price delivery order, valued at $15,640.23, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract has a completion date of May 12, 2025 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, providing a comprehensive...
- This federal contract award is for the delivery of Dupixent 300 mg/2 ml pen 2 ml, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $5,242.91 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a completion date of February 29, 2024 and was awarded on February 28, 2024. This appears to be part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that...
- This federal contract award is for the delivery of Dupixent 300 mg/2 ml pens to the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense. The award was made to Amerisourcebergen Drug Corp, a pharmaceutical distribution company and subsidiary of the parent company Cencora, Inc. The contract has a ceiling value of $12,710.16 and an ultimate completion date of July 20, 2023. It is a delivery order contract with a firm fixed-price pricing type. The contract does not have a...
- This federal contract award is for the delivery of Dupixent 300 mg/2 ml pens to the Defense Logistics Agency (DLA). The contract, valued at $4,088.88, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as the primary vehicle for AmerisourceBergen to...
- The federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of Dupixent 300 mg/2 ml pens. The contract, valued at $4,033.36, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense. The contract is a firm fixed-price delivery order with an ultimate completion date of October 24, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC)...
- This federal contract award is for the delivery of Dupixent 300 mg/2 ml pens to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense. The $11,710.65 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corporation, a major pharmaceutical distribution company. The contract has a period of performance through November 2024 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award is for the delivery of Dupixent 300 mg/2 ml pens to the U.S. Department of Defense (DoD) through the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $33,026.60, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is a firm fixed price delivery order with a period of performance through March 28, 2024....
- This federal contract award is for the delivery of Dupixent 300 mg/2 ml pen, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $3,304.72 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on October 31, 2024 with a completion date of November 1, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, which serves as...
- This federal contract award is for the delivery of Dupixent 300 mg/2 ml pens to the Defense Logistics Agency (DLA). The contract, valued at $10,661.76, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on September 4, 2024. The award is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025. This IDC enables the DLA to efficiently procure a wide range of medical commodities,...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB24FM3F2Delivery Order
This federal contract award is for the delivery of Dupixent 300 mg/2 ml pens to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense. The award, valued at $2,556.44, was made to AmerisourceBergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has an ultimate completion date of January 19, 2024 and is a firm fixed-price delivery order. The contract is not associated with a set-aside designation, indicating it was awarded through full and open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support the healthcare needs of the U.S. military and veteran populations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 1/18/24 |